Elodie Belnoue
Geneve, GE 1211, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Replication-Deficient Lymphocytic Choriomeningitis Virus-Vectored Vaccine Candidate for the Induction of T Cell Immunity against Mycobacterium tuberculosis.
Journal: International journal of molecular sciences
Published: January 26, 2022
STING Agonist Combined to a Protein-Based Cancer Vaccine Potentiates Peripheral and Intra-Tumoral T Cell Immunity.
Journal: Frontiers in immunology
Published: April 14, 2021
A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity.
Journal: Nature communications
Published: December 09, 2020
A TLR7/8 Agonist-Including DOEPC-Based Cationic Liposome Formulation Mediates Its Adjuvanticity Through the Sustained Recruitment of Highly Activated Monocytes in a Type I IFN-Independent but NF-κB-Dependent Manner.
Journal: Frontiers in immunology
Published: July 07, 2020
Targeting self and neo-epitopes with a modular self-adjuvanting cancer vaccine.
Journal: JCI insight
Published: April 24, 2019
In-vivo gp100-specific Cytotoxic CD8+ T Cell Killing Assay.
Journal: Bio-protocol
Published: August 26, 2018
Identification of a novel population of highly cytotoxic c-Met-expressing CD8+ T lymphocytes.
Journal: EMBO reports
Published: February 14, 2017
Enhancing Antitumor Immune Responses by Optimized Combinations of Cell-penetrating Peptide-based Vaccines and Adjuvants.
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: February 29, 2016
Cell-penetrating peptides-the Swiss Army knife of cancer vaccines.
Journal: Oncoimmunology
Published: September 14, 2015
Last Updated: 09/26/2026